

## UNITED STATES PATENT AND TRADEMARK OFFICE

B

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/527,973	08/02/2006	Jairam R Lingappa	UCSF.011.00US	7515	
	7590 09/11/2007	EXAMINER			
JONATHAN ALAN QUINE THE QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C. 2033 CLEMENT AVE. #200 ALAMEDA, CA 94501			KINSEY, NICOLE		
			ART UNIT	PAPER NUMBER	
ALAWEDA, C	(1)7501		1648		
				· · · · · · · · · · · · · · · · · · ·	
			MAIL DATE	DELIVERY MODE	
		•	09/11/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)
		10/527,973	LINGAPPA ET AL.
	Office Action Summary	Examiner	Art Unit
		Nicole E. Kinsey, Ph.D.	. 1648
	The MAILING DATE of this communication app		the correspondence address
Period fo	or Reply		
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANS IN THE MAILING DANS IN THE MAILING DANS IN THE MAILING DANS IN THE MEDIT OF THE MEDIT	ATE OF THIS COMMUNICA 36(a). In no event, however, may a reply vill apply and will expire SIX (6) MONTH , cause the application to become ABAN	ATION.  y be timely filed  S from the mailing date of this communication.  IDONED (35 U.S.C. § 133).
Status			
1) 又	Responsive to communication(s) filed on 14 M	arch 2005.	
	• 10000	action is non-final.	
3)	Since this application is in condition for allowar	nce except for formal matters	s, prosecution as to the merits is
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 1	1, 453 O.G. 213.
Disposit	ion of Claims	•	
·	Claim(s) <u>1-26</u> is/are pending in the application.		
•	4a) Of the above claim(s) is/are withdraw		
	Claim(s) is/are allowed.		
	Claim(s) is/are rejected.		
·	Claim(s) is/are objected to.		
8)⊠	Claim(s) 1-26 are subject to restriction and/or e	election requirement.	
Applicati	ion Papers		•
	The specification is objected to by the Examine		
· ·	The drawing(s) filed on is/are: a) acce		the Examiner
.0/	Applicant may not request that any objection to the		
	Replacement drawing sheet(s) including the correct		
11)	The oath or declaration is objected to by the Ex	· · · · · · · · · · · · · · · · · · ·	•
riority ı	under 35 U.S.C. § 119		
	Acknowledgment is made of a claim for foreign	priority under 35 H.S.C. 8.1	19(a)-(d) or (f)
	☐ All b)☐ Some * c)☐ None of:	priority under 55 0.5.6. § 1	13(a)-(d) of (f).
-/1	1. Certified copies of the priority documents	s have been received.	
	2 Certified copies of the priority documents		lication No
	3. Copies of the certified copies of the prior		
	application from the International Bureau	, , , , , , , , , , , , , , , , , , , ,	•
* 5	See the attached detailed Office action for a list	of the certified copies not re-	ceived.
			•
ttachmen	t(s)		
	ee of References Cited (PTO-892)	4) Interview Sum	
	te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08)	<del></del>	Mail Date rmal Patent Application
	r No(s)/Mail Date	6) Other:	* *

Application/Control Number: 10/527,973

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim 1, with a technical feature of a method for identifying a viral gene required for capsid assembly.

Group II, claim 2, with a technical feature of a composition comprising isolated nucleic acid.

Group III, claim 3, with a technical feature of a method for identifying a compound that inhibits capsid assembly.

Group IV, claim 4, with a technical feature of a composition comprising a compound that inhibits capsid assembly.

Group V, claims 5, 11, 12 and 24, with a technical feature of a method for obtaining one or more host proteins that interact with one or more viral proteins required for capsid assembly.

Group VI, claims 6-8, with a technical feature of a capsid intermediate comprising a host protein.

Group VII, claims 9 and 10, with a technical feature of an antibody to a host protein.

Group VIII, claims 13-19, with a technical feature of a method for identifying compounds that interfere with or inhibit capsid assembly.

Group IX, claims 20-23, with a technical feature of a method for treating symptoms in an animal.

Group X, claims 25 and 26, with a technical feature of an antibody to a viral protein.

Application/Control Number: 10/527,973

Art Unit: 1648

The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I, II, VII, VIII, IX and X do not have a technical feature in common, and thus, lack unity with each other. The technical feature shared among the inventions listed as Groups III and IV is a compound that inhibits capsid assembly, and the technical feature shared among the inventions listed as Groups V and VI is a capsid intermediate comprising a host protein. The noted shared technical features do not provide a contribution over the prior art, as evidenced by the teachings of Sakalian et al. (JOURNAL OF VIROLOGY, June 1996, 70(6):3706-3715). Sakalian et al. discloses a system to determine if a viral protein (e.g., gag mutant) is required for capsid assembly (see Abstract and pages 3709-3710). The system demonstrates that, for example, a mutant gag protein fails to assemble in vitro. Sakalian et al. further discloses use of the cell-free system to identify potential inhibitors (e.g., anti-Gag antibodies) of virus assembly, and Sakalian et al. isolated intermediate assembly complexes with chaperonin (see page 3713). Hence, in the absence of a contribution over the prior art, the noted shared technical feature is not a shared special technical feature. Without a shared special technical feature, the inventions listed as Groups II and IV and Groups V and VI lack unity with one another.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Application/Control Number: 10/527,973

Art Unit: 1648

1/00/10/14d/11bc/: 10/02/,0/

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicole E. Kinsey, Ph.D. whose telephone number is (571) 272-9943. The examiner can normally be reached on Monday through Friday from 8:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

> Nicole E. Kinsey, Ph.D. Examiner Art Unit 1648

/nk/

/Stacy B. Chen/ 8-21-2007 Primary Examiner, TC1600